论文部分内容阅读
目的观察氟伐他汀对急性脑梗死(ACI)患者血清抵抗素水平的影响及意义。方法 ACI患者78例,分为对照组(42例)和治疗组(36例)。对照组患者给予常规药物治疗2 wk;治疗组患者在常规治疗的基础上加用氟伐他汀40 mg,每日1次,口服,治疗2 wk。所有研究对象均测定治疗前后的高敏C-反应蛋白(hs-CRP)和抵抗素,并评定神经功能缺损程度(NDS)评分。结果与治疗前对比,对照组和治疗组患者治疗后的hs-CRP和抵抗素水平均明显下降(P<0.05),但是治疗组较对照组下降更为显著(P<0.05);对照组和治疗组治疗后的NDS均较治疗前下降,但是治疗组NDS的下降较对照组更为显著(P<0.05)。结论氟伐他汀能降低ACI患者抵抗素水平,并有助于其神经功能的恢复。
Objective To observe the effect and significance of fluvastatin on serum resistin in patients with acute cerebral infarction (ACI). Methods 78 patients with ACI were divided into control group (n = 42) and treatment group (n = 36). Patients in the control group were treated with conventional drugs for 2 weeks. Patients in the treatment group were given fluvastatin 40 mg once daily for 2 weeks on the basis of routine treatment. All subjects were measured before and after treatment of high-sensitivity C-reactive protein (hs-CRP) and resistin, and assess the degree of neurological deficit (NDS) score. Results Compared with those before treatment, the levels of hs-CRP and resistin in the control group and the treatment group were significantly decreased (P <0.05), but the treatment group decreased more significantly than the control group (P <0.05) After treatment, the NDS in treatment group decreased compared with that before treatment, but the decline of NDS in treatment group was more significant than that in control group (P <0.05). Conclusion Fluvastatin can reduce the level of resistin in ACI patients and help to restore the neurological function.